Hep C: Six weeks of direct-acting antiviral therapy ‘suboptimal’
An Australian-led study comparing six and 12 weeks of therapy was stopped early, researchers report
Treating recently acquired hepatitis C infection with just six weeks of direct-acting antiviral combination therapy is inferior to a 12-week course, an Australian-led trial shows.
Professor Gail Matthews, of the Kirby Institute at UNSW Sydney, led the international REACT trial in which 188 people six weeks into their sofosbuvir/velpatasvir therapy were randomised to either continue for a further six weeks (standard care) or cease the therapy.
